ATS FORCEFIELD™ TECHNOLOGY



Pristine carbon mechanical heart valve surface, not exposed to blood



Carbon mechanical heart valve surface exposed to human blood – complete platelet coverage

ATS MEDICAL

ATS FORCEFIELD™ TECHNOLOGY

Bench-top human blood flow results



ATS Forcefield™ treated carbon mechanical heart valve surface, exposed to in-vitro human blood – no platelet adhesion or migration



Un-treated carbon mechanical heart valve surface exposed to in-vitro human blood – complete platelet coverage

ATS MEDICAL

ATS FORCEFIELD™ TECHNOLOGY

Acute human clinical study

ATS Forcefield™ treated carbon surface, exposed to human blood flow during cardio-pulmonary bypass – no platelet adhesion

Un-treated carbon surface exposed to human blood flow during cardio-pulmonary bypass – complete platelet coverage

ATS MEDICAL

ATS FORCEFIELD™ TECHNOLOGY

Mitral valve replacement in 90 day animal study —
no long term anti-coagulant or anti-platelet therapy



ATS FORCEFIELD™ TREATED ATS OPEN PIVOT® HEART VALVE

No evidence of thrombus or platelet aggregation

ATS MEDICAL

ATS FORCEFIELD™ TECHNOLOGY

Mitral valve replacement in 90 day animal study —
no long term anti-coagulant or anti-platelet therapy



ATS ForceField™ treated ATS Open Pivot® Valve at 100X
– No evidence of platelets on the valve surface

ATS MEDICAL

ATS FORCEFIELD™ TECHNOLOGY

Mitral valve replacement in 90 day animal study



Un-treated study control valve - visual confirmation of thrombosis

ATS MEDICAL